"This is very, very bad news for anyone who has a diabetes drug under development. This has opened a Pandora's Box. They changed the rules in the middle of the game."
Source
Source
Insider's view: Thank GSK (Avandia) and BMS (Pargluva). Oh, and Schering Plough (Vytorin).... for helping discredit surrogate endpoints.
No comments:
Post a Comment